ArticleGenome medicine2026

Developing a germline prostate cancer risk test incorporating rare and common variants, to inform clinical decisions: a route to precision oncology.

Sarah Wakerell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.